Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 11 Dec 2017 Planned End Date changed from 1 Aug 2022 to 1 Mar 2022.
- 11 Dec 2017 Planned primary completion date changed from 1 Aug 2022 to 1 Nov 2019.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.